Nutra Pharma Corp (NPHC) Current Deferred Revenue (2017 - 2024)

Nutra Pharma has disclosed Current Deferred Revenue across 5 years of filings, most recently posting $236415.0 for Q3 2024.

• In Q3 2024, Current Deferred Revenue fell 34.36% year-over-year to $236415.0; the TTM figure through Sep 2024 stood at $236415.0 (down 34.36% YoY), while the FY2023 annual figure was $233331.0, up 28.55% from the prior year.
• Current Deferred Revenue came in at $236415.0 for Q3 2024 at Nutra Pharma, up from $227762.0 in the prior quarter.
• In the past five years, Current Deferred Revenue ranged from a high of $360149.0 in Q3 2023 to a low of $80410.0 in Q2 2022.
• Average Current Deferred Revenue over 3 years is $225248.9, with a median of $230818.5 recorded in 2023.
• Year-over-year, Current Deferred Revenue surged 288.23% in 2023 and sank 34.36% in 2024.
• Over 3 years, Current Deferred Revenue stood at $181515.0 in 2022, then climbed by 28.55% to $233331.0 in 2023, then gained by 1.32% to $236415.0 in 2024.
• Per Business Quant data, the three most recent Current Deferred Revenue figures were $236415.0 in Q3 2024, $227762.0 in Q2 2024, and $228306.0 in Q1 2024.